http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-105822-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f7ddc4774cf5f8a0bda44a780d73c53d |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K1-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K1-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K1-18 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-28 |
| filingDate | 2016-08-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_beed6a065b04aad89ea6b9d02e669b6a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_808c6da9da0306d6647f40113bf30e43 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b8b1361a6ac22f6f3a4ecfc4b5dd428f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b5e4428f2aecfd8a1b017694a3859817 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_128422e4db00f525fba47e6ee8888824 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0477306820177d56264da69570e57c56 |
| publicationDate | 2017-11-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-105822-A1 |
| titleOfInvention | INSULIN ANALOGS |
| abstract | Claim 1: An insulin analog peptide comprising an A chain of SEQ ID No. 3 indicated in the general formula (1) and a B chain of SEQ ID No. 4 indicated in the general formula (2), (general formula 1): Gly-Ile-Val-Glu-Gln-Cys-Cys-Thr-Ser-Ile-Cys-Ser-Leu-Xaa-G1n-Leu-Glu-Asn-Tyr-Cys-Asn (SEQ ID No. 3) where Xaa it is glutamic acid or asparagine; and (general formula 2): Phe-Val-Asn-Gln-His-Leu-Cys-Gly-Ser-His-Leu-Val-Glu-Ala-Leu-Tyr-Leu-Val-Cys-Gly-Glu-Arg -Gly-Phe-Xaa-Tyr-Thr-Pro-Lys-Thr (SEQ ID No. 4) where Xaa is phenylalanine or is suppressed. Claim 8: A nucleic acid encoding the insulin analog peptide according to any one of claims 1 to 7. Claim 11: A transformant that is transformed with the recombinant expression vector according to claim 10. Claim 13: A a method for preparing the insulin analog peptide according to claim 1, comprising: a) the preparation of a recombinant expression vector comprising a nucleic acid encoding the insulin analog peptide according to claim 1; b) the transformation of the recombinant expression vector into a host cell and obtaining a transformant thereof; c) culture of the transformant and expression of the insulin analog peptide; and d) isolation and purification of the expressed insulin analog peptide. Claim 17: A pharmaceutical composition for the treatment of diabetes comprising the insulin analog peptide according to any one of claims 1 to 7 and a pharmaceutically acceptable carrier. |
| priorityDate | 2015-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 35.